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PGS9
THE COST-EFFECTIVENESS OF HIGH DOSE
ORAL VERSUS INTRAVENOUS PROTON PUMP
INHIBITION IN HIGH-RISK PATIENTS WITH
BLEEDING PEPTIC ULCERS HAVING
UNDERGONE THERAPEUTIC ENDOSCOPY
Barkun A1,Adam V1, Kennedy WA2, Fallone CA1, Herba K1,
Bardou M1
1McGill University Health Centre, Montreal, QC, Canada;
2University of Montreal, Montreal, QC, Canada
OBJECTIVES: Management of patients with bleeding
ulcers has evolved over the past ﬁve years, partly due to
the use of high dose intravenous, and more recently high
dose oral proton pump inhibitors (PPI’s). We compared
the cost effectiveness of the two. METHODS: Patients
with bleeding ulcers initially treated endoscopically for
high risk stigmata of re-bleeding were considered. The
model structure, deﬁned and validated by clinical experts,
evaluated rebleeding within 30 days. Probabilities were
determined from published literature. Charges and length
of stays (LOS) were obtained from a 20% random sample
of the NIS2000 (Nation-wide Inpatient Sample) adminis-
trative database. Pharmacological costs of high dose 
40mg Po BID ¥ 5 days and 80mg IV bolus followed by
8mg/hr ¥ 3 days were tabulated separately from the 
hospitalization costs. A third party payer perspective was
adopted; 2001 $US were used. Sensitivity and threshold
analyses were carried out. RESULTS: Mean LOS and
costs for patients admitted with uncomplicated and com-
plicated ulcer bleeding were 3 and 4.7 days, and $7993
and $11,802 respectively. Re-bleeding rates for patients
receiving oral or IV therapy were 7.3% and 5.9%. No
strategy dominated in base-case analysis: IV PPI cost
$14.90 more and was 1.44% more effective than oral PPI.
IV PPI became dominant when IV PPI re-bleeding rate
dropped below 5% or oral PPI re-bleeding rate rose over
8%. No differences in conclusions were noted over a wide
range of cost estimates. CONCLUSIONS: Based on pub-
lished data, high dose IV PPI for 3 days or oral proton
pump inhibition for ﬁve days were almost equivalent in
terms of outcomes with the IV form being slightly more
effective and more costly according to base case analysis
estimates. Prospective trials in Western patients are
required to conﬁrm the increased effectiveness, and sub-
sequently, the cost-effectiveness of high dose oral PPI.
PGS10
TREATMENT PATTERNS AND HEALTH CARE
COSTS OF MEBEVERINE-TREATED IBS
PATIENTS:A CASE-CONTROL STUDY
Goettsch WG1, van den Boom G2, Breekveldt N1, Smout A3,
Herings RMC1
1PHARMO Institute, Utrecht, Netherlands; 2Novartis Pharma,
Arnhem, Netherlands; 3University Medical Centre, Utrecht,
Netherlands
OBJECTIVES: To assess treatment patterns and associ-
ated health care cost in mebeverine users relative to
matched controls. METHODS: A matched case-control
study was performed using pharmacy data. Cases were
mebeverine users as proxy for IBS patients. Controls 
were non-mebeverine users and matched to cases by 
age, gender and pharmacy. Prevalence and incidence of
mebeverine use were estimated and concomitant drug 
use and hospitalisations were assessed in 3431 cases and
3431 controls. Concomitant drug use and hospitalisa-
tions was also assessed in a subgroup of 1222 users of
mebeverine and laxatives (proxy for constipation-IBS)
and their controls. RESULTS: Twelve per 1000 residents
were ever-dispensed mebeverine in 1998. One-third of
these mebeverine users used laxatives concomitantly.
Total concomitant drug use and hospitalisations were
increased in mebeverine users. The odds ratio for hospi-
talisations for gastrointestinal reasons was increased 
predominantly in mebeverine users with concomitant lax-
ative use (OR: 8.7; 95% CI = 4.3–17.3). Excess yearly
costs for all concomitant medications were €94 (95% 
CI = €79–€109) and for hospital admissions €120
(€74–€166) per mebeverine user. In mebeverine users with
concomitant laxative use these costs were €136 and €251
respectively. CONCLUSIONS: In the Netherlands only a
proportion of IBS patients is treated medically. In treated
patients, concomitant drug use and hospitalisations are
increased relative to matched controls. Medical resource
use and associated health care costs are particularly
increased in mebeverine users using laxatives, indicating
that constipation-predominant IBS is relative costly. The
total mean excess cost per patient per year is €480.
PGS11
INCIDENCE AND COST OF LAPAROSCOPIC
CHOLECYSTECTOMY IN THE US MANAGED
CARE POPULATION
Hanna DB, Zhao SZ, Barr CE
Pharmacia Corporation, Peapack, NJ, USA
OBJECTIVES: To estimate the incidence and cost of LC
in the US managed care population and determine if
patient characteristics affect the ratio of LC performed 
in inpatients versus outpatients. METHODS: MEDSTAT
MarketScanTM Commercial Claims and Encounters Data-
base (CCED) contains inpatient (IP) and outpatient (OP)
claims from over 2.5m people in 45 large U.S. employer-
sponsored plans and recorded 366,674 adult IP admis-
sions in 1999–2000. LC procedures were identiﬁed by
ICD-9-CM and CPT-4 codes. Annual LC incidence rate
was determined by percentage of persons age 18–65
undergoing LC within the average total CCED popula-
tion in 1999–2000. Proportion of IP LC among all admis-
sions was estimated. Proportions of IP and OP LC for all
patients and by age, gender, and primary diagnosis were
determined and compared by chi-square or Wilcoxon
tests. Cost of LC was estimated within study groups.
RESULTS: We identiﬁed 22,598 LC patients (IP 21.4%;
OP 78.6%). Average annual LC incidence rate was
0.85%. Approximately 1.32% of all hospital admissions
were for LC. 76.65% of LC patients were female. IP 
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proportion was signiﬁcantly higher in males than females
(25.7% vs. 20.0%, p < 0.001). Overall mean age was
45.84 (IP 46.64; OP 45.62, p < 0.001). Proportion of 
IP among all LCs was signiﬁcantly higher among older
people (18–34y: 20.4%; 35–44y: 19.9%; 45–54y:
20.2%; 55–65y: 24.7%, p < 0.001). IP proportions by
diagnosis were: calculus of the gall bladder and/or bile
duct, 31.8%; other gall bladder disorders (including
cholecystitis), 13.9%; diseases of the pancreas, 87.6%;
and all other diagnoses, 41.3% (p < 0.001). Mean net
cost for LC hospital admission was $9168 (95% CI:
$8913–$9424) and average LOS was 3.6 days (95% CI:
3.4–3.8). Net OP procedure cost for LC was $3158 (95%
CI: $3123–$3194). CONCLUSIONS: Nearly 80% of
LCs in the US managed care population were ambulatory-
based. Patients undergoing IP LC were signiﬁcantly dif-
ferent from patients undergoing OP LC in age, gender,
and primary diagnosis. Cost of hospital-based LC was
almost three times higher than cost of ambulatory-based
LC.
PGS12
COST-MINIMIZATION ANALYSIS OF A
PHARMACIST-DIRECTED, PANTOPRAZOLE
INTRAVENOUS TO ORAL DOSAGE FORM
CONVERSION PROGRAM
Taylor MD1, Greenwood K2, Johns T2, Schmidt JC3, Segal R1,
Hatton R2
1University of Florida, Gainesville, FL, USA; 2Shands at the
University of Florida, Gainesville, FL, USA; 3Shands
HealthCare, Gainesville, FL, USA
OBJECTIVE: Several medications are equally efﬁcacious
regardless of dosage form. This study conducted a cost-
minimization analysis from an institutional perspective 
of a pharmacist-directed intravenous to oral conversion
program for pantoprazole, a proton pump inhibitor (PPI).
Empirical evidence supports equivalence of IV and tablet
forms of pantoprazole in inhibiting gastric acid secretion.
METHODS: Patients on IV pantoprazole in select units
at a tertiary care teaching hospital between March 15,
2002 and April 12, 2002 were included in the interven-
tion group. Following a protocol approved by the Phar-
macy & Therapeutics Committee, a pharmacist evaluated
patients to determine eligibility for conversion to admin-
istration by mouth or nasogastric tube. The pharmacist
recorded times required to identify and switch patients.
Average times required for preparation, dispensing, and
administration of dosage forms were determined via
employee interview. Medication acquisition and labor
costs were obtained from the hospital ﬁnancial depart-
ment. Proportion of days therapy with each dosage form
for the intervention group and historical control group,
which otherwise met identical inclusion criteria, were
determined from the pharmacy database. RESULTS: A
signiﬁcant difference in proportion of days therapy with
PPI dosage forms existed between control (N = 182) and
intervention (N = 150) groups (C2 = 276.39, df = 2, p <
0.05). The intervention increased total proportion of days
therapy with pantoprazole tablets and PPI suspensions by
6.9% and 22.0%, respectively. Days therapy with IV 
pantoprazole were decreased by 28.8% (from 61.2% to
32.4%). Applying costs for medications, supplies, and
labor, the conversion program saves $13.45/patient
started on IV pantoprazole. Projecting cost saving to 1
year with 1887 patients/year, the conversion program
could save $25,380.15 in the hospital budget. CON-
CLUSION: A pharmacist-directed intravenous to oral
dosage form conversion program can result in institu-
tional cost savings. However, cost savings are dependent
on success in converting patients. Cost savings would 
be increased to $18.50/patient on IV pantoprazole by
shifting an additional 6.9% of PPI therapy days from IV
pantoprazole to pantoprazole tablets.
GASTROINTESTINAL DISEASES/DISORDERS—
Quality of Life/Preference Based Outcomes
PGS13
DIFFERENCES BETWEN ELDERLY AND
YOUNGER ADULTS IN THE EPIDEMIOLOGY
AND TREATMENT OF SYMPTOMATIC GERD
AND NOCTURNAL GERD
Ricci JA1, Engelhart LM2, Sloan S2
1IMR, An AdvancePCS Company, Hunt Valley, MD, USA;
2Janssen Pharmaceutica,Titusville, NJ, USA
OBJECTIVE: To compare the epidemiology and treat-
ment of GERD and nocturnal GERD in a U.S. national
sample of elderly (65+ years of age) and younger adults
(<65 years of age). METHODS: A national random-
sample phone survey of 9035 adults identiﬁed 171 elderly
and 1090 younger adults with symptomatic GERD, and
42 elderly and 329 younger adults with nocturnal GERD.
Symptomatic GERD cases reported heartburn or regurgi-
tation 1+ time/week in past three months. Nocturnal
GERD was deﬁned as symptomatic GERD with 1+
nocturnal symptom 1+ time/week. Severe was deﬁned as
2+ episodes/week. The interview included questions on
symptom frequency, concomitant motility-related symp-
toms, and treatment for GERD symptoms. Chi-square
tested for statistical signiﬁcance between elderly and
younger adults. RESULTS: Prevalence of symptomatic
GERD (9.9% vs. 14.9%; p < 0.0001) and nocturnal
GERD (2.4% vs. 4.5%; p < 0.0001) was lower and less
severe (74% vs. 87%; p < 0.05) in elderly than younger
adults. Most bothersome symptoms were regurgitation in
elderly, and heartburn in younger adults. Among GERD
cases, motility-related symptoms (e.g., post-prandial full-
ness, early satiety) were less prevalent or less frequent in
the elderly than younger adults. Among nocturnal GERD
cases, prevalence of motility-related symptoms was not
different between elderly and younger adults, but the
elderly reported less severe post-prandial fullness (p <
0.05) and a lower frequency of nausea (p < 0.001) than
younger adults. Prescription medication use for GERD-
related symptoms was reported by 24% of nocturnal
GERD cases and did not differ by age. However, elderly
